The State of Medicine Quality in the Mekong Sub-Region
Sauwakon Ratanawijitrasin & Souly Phanouvong
IRASEC, Bangkok
décembre 2014, 88 p.
ISBN : 978-616-7571-19-5
English text
This study aims to increase awareness and interest on the pharmaceutical quality and counterfeit medicines issues in the Mekong Subregion.
It provides a review of existing empirical findings regarding the state of medicine quality in the region. It also analyzes data on quality testing of drug samples from the five countries (Cambodia, China, Lao PDR, Thailand and Vietnam) in the region, in order to develop a conceptual framework for addressing the issue at the regional level, and to suggest areas for further study.
Table of contents
Introduction
1. The Mekong Subregion and medicine quality
2. The Mekong Subregion medicine quality study
3. Medicine quality as reflected in the five country study
4.The multiple requirements of medicine quality
5. Regulation medicine : regulatory spheres and gap
6. The ’demand’ for poor quality medicines
7. Improving the state of medicine quality in the Mekong Subregion
References
Annexes
—
The authors
Dr. Sauwakon Ratanawijitrasin is an expert in health and pharmaceutical policies, and system design. She has conducted research and published in the areas of drug policy, drug regulation, supply, quality, utilization, information, health insurance, and health services, in institutional, national and international contexts. She has also advised governments and international organizations, such as WHO, MSH, USP. Dr. Sauwakon currently teaches at Mahidol University.
Souly Phanouvong is currently the Manager for Asia Programs of the United States Pharmacopeia’s Promoting the Quality of Medicines program, funded by the United States Agency for International Development. In early 2000, he worked for WHO in Geneva as a technical officer for promoting access to high-quality anti-tuberculosis medicines. He has over 25 years of international experiences in the areas of medicines quality assurance and policy from both advanced and less advanced regulatory settings. He holds a B.Sc. (Pharm), a Pharm.D and two PhDs.
